Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration

被引:84
|
作者
Chakravarthy, Usha [1 ,2 ]
Goldenberg, Dafna [3 ,4 ]
Young, Graham [2 ]
Havilio, Moshe [5 ]
Rafaeli, Omer [5 ]
Benyamini, Gidi [5 ]
Loewenstein, Anat [3 ,4 ]
机构
[1] Queens Univ Belfast, Ctr Expt Med Dent & Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland
[2] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland
[3] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Notal Vis Ltd, Tel Aviv, Israel
关键词
OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; RANIBIZUMAB; SEGMENTATION; BEVACIZUMAB; IMAGES;
D O I
10.1016/j.ophtha.2016.04.005
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The objective of the study was to evaluate the accuracy of the Notal OCT Analyzer (NOA) versus that of a retina specialist (RS) in the automated detection of fluid on optical coherence tomography (OCT). Design: A study of the performance of the NOA compared with the results from 3 RSs. Participants: A selection of 155 anonymized OCT scans (Zeiss Cirrus; Carl Zeiss Meditec, Dublin, CA) from an image repository at a single tertiary referral retina center (Belfast Health and Social Care Trust, Belfast, United Kingdom) after approval from the local data guardian of the clinical site. Methods: One hundred fifty-five OCT cube scans were stripped of all clinical identifiers and exported. The NOA and 3 independent RSs analyzed all 128 B-scans of each cube scan for the presence of intraretinal fluid, subretinal fluid, and suberetinal pigment epithelium fluid. The NOA also ranked individual B-scans of each volume scan for likelihood of CNV activity, which was subjected to a second grading session by the 3 RSs. Main Outcome Measures: The NOA's sensitivity and specificity versus the RS grading and the NOA's performance in ranking B-scans for activity. Results: One hundred forty-two cube scans met the inclusion criteria for the primary analysis. On testing the RS grading versus the NOA, the accuracy was 91% (95% confidence interval [CI], +/- 7%), sensitivity was 92% (95% CI, +/- 6%), and specificity was 91% (95% CI, +/- 6%), meeting the primary outcome. The graders' accuracy when compared with the majority of the other graders (including a fourth grader) was 93%. On average, the 3 graders could identify fluid in 95% of scans by just reviewing a single cross-section with the highest NOA score and 99.5% of scans with fluid by viewing the top 3 cross-sections. Conclusions: Concordance between the NOA and the RS determination of lesion activity was extremely high. The level of discrepancy between the RS and the NOA results was similar to the NOA's mismatches. Our results show that automated delineation of the retinal contours combined with interpretation of disease activity is feasible and has the potential to become a powerful tool in terms of its clinical applications. (C) 2016 by the American Academy of Ophthalmology.
引用
收藏
页码:1731 / 1736
页数:6
相关论文
共 50 条
  • [1] Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article
    Miotto, Stefania
    Zemella, Nicola
    Gusson, Elena
    Panozzo, Giacomo
    Saviano, Sandro
    Scarpa, Giuseppe
    Boschi, Giorgio
    Piermarocchi, Stefano
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (03) : 298 - 308
  • [2] Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
    Pitlick, Jamie M.
    Vecera, Kayla F.
    Barnes, Kylie N.
    Reski, John W.
    Forinash, Alicia B.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (02) : 290 - 296
  • [3] Aflibercept for neovascular age-related macular degeneration
    Sarwar, Salman
    Clearfield, Elizabeth
    Soliman, Mohamed Kamel
    Sadiq, Mohammad Ali
    Baldwin, Andrew J.
    Hanout, Mostafa
    Agarwal, Aniruddha
    Sepah, Yasir J.
    Do, Diana V.
    Quan Dong Nguyen
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [4] Ranibizumab in neovascular age-related macular degeneration
    Eng, Kenneth T.
    Kertes, Peter J.
    CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) : 451 - 466
  • [5] Neovascular Age-Related Macular Degeneration
    Veritti, Daniele
    Sarao, Valentina
    Lanzetta, Paolo
    OPHTHALMOLOGICA, 2012, 227 : 11 - 20
  • [6] RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Kaiser, Peter K.
    Wykoff, Charles C.
    Singh, Rishi P.
    Khanani, Arshad M.
    Do, Diana V.
    Patel, Hersh
    Patel, Nikhil
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (08): : 1579 - 1586
  • [7] Preferred therapies for neovascular age-related macular degeneration
    Chiang, Allen
    Regillo, Carl D.
    CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 199 - 204
  • [8] Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration
    Cohen, Salomon Yves
    Maloberti, Bertrand
    Fajnkuchen, Franck
    Nghiem-Buffet, Sylvia
    Delahaye-Mazza, Corinne
    Grenet, Typhaine
    Quentel, Gabriel
    OPHTHALMOLOGICA, 2014, 231 (02) : 80 - 85
  • [9] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Verner-Cole, E. A.
    Davis, S. J.
    Lauer, A. K.
    DRUGS OF TODAY, 2012, 48 (05) : 317 - 329
  • [10] Intravitreal bevacizumab for neovascular age-related macular degeneration
    Ladewig, M. S.
    Ziemssen, F.
    Jaissle, G.
    Helb, H. -M.
    Scholl, H. P. N.
    Eter, N.
    Bartz-Schmidt, K. U.
    Holz, F. G.
    OPHTHALMOLOGE, 2006, 103 (06): : 463 - +